Palovarotene for Fibrodysplasia Ossificans Progressiva ( <scp>FOP</scp> ): Results of a Randomized, Placebo‐Controlled, Double‐Blind Phase 2 Trial-Reference-Cited by-同舟云学术

Palovarotene for Fibrodysplasia Ossificans Progressiva ( FOP ): Results of a Randomized, Placebo‐Controlled, Double‐Blind Phase 2 Trial

Published:2022-08-17 Issue:10 Volume:37 Page:1891-1902
ISSN:0884-0431
Container-title:Journal of Bone and Mineral Research
language:en
Short-container-title:J of Bone & Mineral Res

Author:

Pignolo Robert J.¹^ORCID,Baujat Geneviève²,Hsiao Edward C.³,Keen Richard⁴,Wilson Amy⁵,Packman Jeff⁵,Strahs Andrew L.⁵,Grogan Donna R.⁵,Kaplan Frederick S.⁶

Affiliation:

1. Department of Medicine, Divisions of Geriatric Medicine and Gerontology, Hospital Internal Medicine, and Endocrinology, Robert and Arlene Kogod Center on Aging Mayo Clinic Rochester MN USA

2. Departement de Genetique Institut IMAGINE and Hôpital Necker‐Enfants Malades Paris France

3. Division of Endocrinology and Metabolism, UCSF Metabolic Bone Clinic, Institute for Human Genetics, Institute for Regeneration Medicine, and the Program for Craniofacial Biology University of California‐San Francisco San Francisco CA USA

4. Consultant Rheumatologist & Honorary Senior Lecturer in Metabolic Bone Disease The Royal National Orthopaedic Hospital Stanmore UK

5. Ipsen Newton MA USA

6. Departments of Orthopaedic Surgery and Medicine, and The Center for Research in FOP and Related Disorders, Perelman School of Medicine University of Pennsylvania Philadelphia PA USA

Publisher

Wiley

Subject

Orthopedics and Sports Medicine,Endocrinology, Diabetes and Metabolism

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jbmr.4655

Reference36 articles.

1. Epidemiology of the Global Fibrodysplasia Ossificans Progressiva (FOP) Community

2. Fibrodysplasia ossificans progressiva: diagnosis, management, and therapeutic horizons;Pignolo RJ;Pediatr Endocrinol Rev,2013

3. Quality of life of patients with fibrodysplasia ossificans progressiva

4. Fibrodysplasia ossificans progressiva. The clinical features and natural history of 34 patients

5. Early Mortality and Cardiorespiratory Failure in Patients with Fibrodysplasia Ossificans Progressiva

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nitrogen-containing heterocyclic drug products approved by the FDA in 2023: Synthesis and biological activity;European Journal of Medicinal Chemistry;2024-12

2. A comprehensive review of small molecule drugs approved by the FDA in 2023: Advances and prospects;European Journal of Medicinal Chemistry;2024-10

3. Analysis of the Actions of RARγ Agonists on Growing Osteochondromas in a Mouse Model;International Journal of Molecular Sciences;2024-07-11

4. Fibrodysplasia ossificans progressiva (clinical observation with a brief review of the literature);N.N. Priorov Journal of Traumatology and Orthopedics;2024-07-04

5. Interleukin 1 receptor antagonist as biomarker for disease flares in fibrodysplasia ossificans progressiva;Bone;2024-07